List of Contract Research Companies in Turkey - 2

Search through the full list with powerful filtering options

Company	About
Inpharmus Esentepe Mahallesi, Buyukderece Caddesi, Kanyon Ofis Blogu No:185 Kat:14 Levent-Sisli, Istanbul, 34394, TR	Inpharmus, formerly known as TRPharm, is a pharmaceutical company established in 2013 that focuses on innovative treatments for emerging markets. With a presence in nearly 20 countries and operations in 12, Inpharmus has offices in Istanbul and Dubai, serving as a significant player in the healthcare sector across the Middle East, Turkey, Africa, Russia, and the CIS region. The company offers a variety of services aimed at improving patient outcomes, including clinical research management, scientific study recovery, and early access programs for innovative treatments. Inpharmus develops, manufactures, and distributes therapies across multiple therapeutic areas to address unmet medical needs. The company collaborates with global partners, such as Fennec Pharmaceuticals, to enhance its reach and impact in emerging markets. Inpharmus is committed to bridging the gap between diagnosis and treatment, ensuring that patients receive effective care.
RS Research Teknopark Istanbul, Sanayi Mah. Teknopark Blv., No:1/2A 401, Istanbul, Pendik 34912, TR	RS Research is a clinical-stage biotechnology start-up based in Epalinges, Switzerland, with an additional location in Istanbul, Turkey. Founded in 2015, the company specializes in discovering and developing smart nanomedicines aimed at targeted cancer therapy. The company provides services for pre-clinical studies, utilizing its expertise in innovative drug delivery platforms to support the development of nanomedicines. RS Research's product pipeline includes smart nanomedicines like Sagitta® and Dui, which enhance the therapeutic index and manufacturability of treatments, and RS-0139, a drug candidate currently in Phase I clinical trials that targets tumors with specific receptors. RS Research is committed to advancing its technologies through research and development, as evidenced by its presentations at international conferences. The leadership team includes Co-Founder and Chief Scientific Officer Rana Sanyal and Co-Founder and Chief Operating Officer Sena Nomak.

Company

About

Inpharmus

Esentepe Mahallesi, Buyukderece Caddesi, Kanyon Ofis Blogu No:185 Kat:14 Levent-Sisli, Istanbul, 34394, TR

Inpharmus, formerly known as TRPharm, is a pharmaceutical company established in 2013 that focuses on innovative treatments for emerging markets. With a presence in nearly 20 countries and operations in 12, Inpharmus has offices in Istanbul and Dubai, serving as a significant player in the healthcare sector across the Middle East, Turkey, Africa, Russia, and the CIS region. The company offers a variety of services aimed at improving patient outcomes, including clinical research management, scientific study recovery, and early access programs for innovative treatments. Inpharmus develops, manufactures, and distributes therapies across multiple therapeutic areas to address unmet medical needs. The company collaborates with global partners, such as Fennec Pharmaceuticals, to enhance its reach and impact in emerging markets. Inpharmus is committed to bridging the gap between diagnosis and treatment, ensuring that patients receive effective care.

RS Research

Teknopark Istanbul, Sanayi Mah. Teknopark Blv., No:1/2A 401, Istanbul, Pendik 34912, TR

RS Research is a clinical-stage biotechnology start-up based in Epalinges, Switzerland, with an additional location in Istanbul, Turkey. Founded in 2015, the company specializes in discovering and developing smart nanomedicines aimed at targeted cancer therapy. The company provides services for pre-clinical studies, utilizing its expertise in innovative drug delivery platforms to support the development of nanomedicines. RS Research's product pipeline includes smart nanomedicines like Sagitta® and Dui, which enhance the therapeutic index and manufacturability of treatments, and RS-0139, a drug candidate currently in Phase I clinical trials that targets tumors with specific receptors. RS Research is committed to advancing its technologies through research and development, as evidenced by its presentations at international conferences. The leadership team includes Co-Founder and Chief Scientific Officer Rana Sanyal and Co-Founder and Chief Operating Officer Sena Nomak.